Here are some resources.
Path to Notified Body public documents:
www.team-nb.org/index.php?option=com_docman&task=cat_view&gid=17&Itemid=38
The attached GHTF documents are more current than the attached
MEDDEV documents.
From the European perspective, it is very clear that PMCFU is a subset of Post Market Surveillance. The latest European Medical Device Directives (MDD Annex X for example) mentions that if you are not planning to do PMCFU it must be "duly justified" whereas there is no getting out of doing Post Market Surveillance if you are following MDD Annex II (Full QA System) approach. MDD Annex X says:
The clinical evaluation and its documentation must be actively updated
with data obtained from the post-market surveillance. Where post-market
clinical follow-up as part of the post-market surveillance plan for the
device is not deemed necessary, this must be duly justified and documented.
Hope this helps.
Sam Lazzara